Research in ContextEvidence before this studyRecurrent pregnancy loss (RPL) is defined as three or more consecutive miscarriages, and it affects 2--5% of couples. Often, it has been seen in patients suffering from RPL without knowing the cause. Up to now, numerous studies have been conducted to identify predictive factors that lead to RPL, nevertheless, the exact molecular mechanism underlying RPL are still not well understood yet. Over the past 15 years, our group has investigated the molecular mechanisms underlying RPL, and we identified and reported that the cleaved form of inter-α trypsin inhibitor-heavy chain 4 (ITI-H4) is expressed in a large proportion of RPL patients.Added value of this studyHere, we expand our understanding and demonstrate that ITI-H4, a key factor for RPL, could be modulated by plasma kallikrein (KLKB1) through the IL-6 signaling network, and the present study points to the opposing roles of the long isoform of ITI-H4 and ITI-H4 (ΔN^688^) in modulating inflammatory tolerance, cell invasion, migration, and proliferation.Implications of all the available evidenceTaken all together, these results suggest that the ITI-H4 (ΔN^688^) might be a crucial inflammatory factor which contributes to the pathogenesis of RPL. This is the first study on a novel cellular mechanism underlying RPL.Alt-text: Unlabelled Box

1. Introduction {#s0020}
===============

Recurrent pregnancy loss (RPL) is a reproductive disorder which takes place in 2--5% of pregnancy women \[[@bb0005],[@bb0010]\]. At present, increasing lines of evidence support the notion that RPL is a proinflammatory condition, and several research papers showed that pregnancy is a well-controlled systemic inflammatory condition \[[@bb0015], [@bb0020], [@bb0025], [@bb0030]\]. A successful pregnancy requires strict temporal regulation of maternal immune function to accommodate the 'foreign' semi-allergenic fetus \[[@bb0035]\]. In addition, immunological causes for pregnancy loss include a problem within the embryo such that the signals to the maternal immune cells are inappropriate or a problem within the maternal immune cells \[[@bb0040], [@bb0045], [@bb0050], [@bb0055]\]. T cells during normal pregnancy predominantly secrete anti-inflammatory cytokines (Th2 response) compared with increased pro-inflammatory cytokines (Th1 response) observed in patients with RPL, and the ratio of Th1 activity to Th2 activity is critical for normal pregnancy \[[@bb0050],[@bb0055]\].

In a previous study, we used blood samples to identify altered protein expression in RPL patients undergoing *in vitro* fertilization (IVF) treatment \[[@bb0060]\]. One of these proteins, inter-α-trypsin inhibitor heavy chain 4 (ITI-H4), was weakly expressed at a molecular weight of 120 kDa, but was highly expressed at a modified molecular weight of 36 kDa in RPL patients. ITI-H4 is one of acute phase proteins, and the high expression of ITI-H4 in early liver development and explants treated with IL-6 suggests an important role in liver formation \[[@bb0065]\]. It was demonstrated that the IL-6 signaling pathway plays important roles in the regulation of diverse development and biological processes \[[@bb0070]\]. Furthermore, the high level of STAT3 expression in the luminal epithelium and stromal cells during pre-implantation period might be essential for establishing uterine receptivity \[[@bb0075]\]. ITI-H4 is the only member of the ITI family which harbors a kallikrein-released bradykinin-like domain in its C-terminal sequence, making its plasma kallikrein sensitive \[[@bb0080]\]. The cleaved form detected in the various subjects with enhanced estrogen levels may contribute to increased cleavage of ITI-H4 by elevating levels of circulating kallikrein in the serum \[[@bb0080]\]. In addition, plasma kallikrein is known to be expressed in hormone-dependent tissues such as the breast and ovary \[[@bb0085]\]. To date, the function of ITI-H4 *via* IL-6 signaling pathway in RPL-linked inflammatory is yet to be reported. More importantly, its action and molecular mechanism requires characterization.

In this study, we observed significantly upregulated ITI-H4 (∆N^688^) in serum derived from RPL patients using large-scale samples. We evaluated the expression of ITI-H4 and plasma kallikrein (KLKB1) in the PBMCs of RPL patients and controls, and explored the molecular mechanism of ITI-H4\'s action in the development of inflammation. Our data demonstrate that inflammatory stimuli also upregulated the ITI-H4 (∆N^688^) and KLKB1 expression *in vitro*. Here, we suggest that the long isoform of ITI-H4 and ITI-H4 (∆N^688^) could perform opposing functions during the maintenance of pregnancy. In addition, KLKB1 might contain essential regulatory functions on this process *via* IL-6 signaling pathway.

2. Materials and methods {#s0025}
========================

2.1. Subjects and samples {#s0030}
-------------------------

This study was approved by the Ethics Committee of CHA General Hospital located in Seoul, Korea. Informed written consents were obtained from all participants and this study with human blood samples was approved by an Institutional Review Board (Reference Number: 08--16). Subjects with regular menstrual cycles were selected and blood samples were collected from them on the 5-9^th^ days after ovulation of the menstrual cycle. Venous blood samples were prepared as previously described \[[@bb0060]\]. Human peripheral blood mononucleated cells (PBMC) were collected from patients who visited the Fertility Center of the CHA General Hospital in Korea. The control subjects were selected from women with no obstetric complications or history of miscarriage ([Table 1](#t0005){ref-type="table"}). Information on the abortion history for each RPL patient is listed in Supplemental Table 1.Table 1Clinical and biochemical profiles of 30 normal controls and 60 patients with recurrent pregnancy loss (RPL).Table 1CharacteristicsControl (n = 30)RPL (n = 60)*p*-valueAge (y)31.9 ± 4.532.6 ± 5.2NSBMI (kg/m^2^)24.8 ± 2.526.3 ± 1.7NSGravidity (n)2.5 ± 1.75.3 ± 2.6\< .005[⁎⁎](#tf0010){ref-type="table-fn"}Parity (n)1.8 ± 0.61.4 ± 0.2\< .05[⁎](#tf0005){ref-type="table-fn"}Previous pregnancy losses (wk)--7.8 ± 1.5--Spontaneous abortion (no.)0 ± 03.6 ± 0.8\< .05[⁎](#tf0005){ref-type="table-fn"}No. of Primary RPL (n)--42--No. of Secondary RPL (n)--18--[^1][^2][^3]

2.2. Cell culture {#s0035}
-----------------

JEG-3 cells (placental choriocarcinoma cell line) were grown in Dulbecco\'s modified Eagle\'s medium (DMEM, GIBCO BRL, Rockville, MD, USA), and PBMC (peripheral blood mononuclear cell) and THP1 (acute monocytic leukemia cell line, ATCC TIB-202) were grown in RPMI 1640 medium supplemented with 10% FBS (fetal bovine serum, GIBCO BRL) and 1% penicillin and streptomycin (GIBCO BRL), respectively. The cells were grown at 37 °C in the presence of 5% carbon dioxide in a humidified incubator.

2.3. Construction of expression vectors {#s0040}
---------------------------------------

Isolation of the full-length cDNA for ITI-H4 from HepG2 cells (human hepatoma, ATCC HB-8065) was performed and the cDNA coding sequence of human ITI-H4 in GenBank (accession no. [NM_002218](ncbi-n:NM_002218){#ir0005}) was subcloned into an expression vector. pCS4-3Flag vector expressing ITI-H4 was constructed by cloning the long and ∆N^688^ isoforms of PCR product of human ITI-H4 using nPfu-Forte DNA Polymerase (Enzynomics, Daejeon, Korea). KLKB1 was subcloned into pcDNA3-6myc expression vector. Expression constructs of ITI-H4 are as following: pCS4-3Flag-long ITI-H4, aa 1--902; pCS4-3Flag-ITI-H4 (∆N^688^), aa 689--902; and pCS4-3Flag-ITI-H4 (∆BKD), ∆aa 661--688.

2.4. Isolation of human monocyte-derived macrophages {#s0045}
----------------------------------------------------

Peripheral blood mononuclear cells (PBMCs) from healthy women (6--8 samples for each experiment) at CHA General Hospital were isolated by Ficoll density gradient centrifugation and purified with human CD14+ MicroBeads (MiltenyiBiotec, BergischGladbach, Germany) according to the manufacturer\'s instructions. Monocytes were cultured in RPMI 1640 supplemented with 10% fetal calf serum for 7--10 days until differentiation into macrophages.

2.5. Flow cytometric assay of cytokine expression {#s0050}
-------------------------------------------------

The concentrations of cytokines in the supernatants of the treated cell cultures were measured with the BD Cytometric Bead Array Human Th1/Th2/Th17 Inflammatory Cytokines Kit (BD Biosciences, San Jose, CA, USA), according to the manufacturer\'s instructions.

2.6. KLKB1 activity assay {#s0055}
-------------------------

Serum samples (5 μL) were added in duplicate to 50 μL of the H-Pro-Phe-Arg-AMC (Bachem, Bubendorf, Liestal, Switzerland) substrate with activity buffer (50 mM Tris, 250 mM NaCl, PH 7.5). After a 5 min 25 °C incubation, fluorescence was recorded (excitation 380 nm; emission 460 nm) using a Flexstation 3 microplate reader. This assay was validated by the addition of 2.5 μg of human plasma extracted KLKB1 (Calbiochem-Merch, Nottingham, UK) to 50 μL of the substrate in activity buffer.

2.7. Western blot analysis {#s0060}
--------------------------

Cells were lysed in a lysis buffer (150 mM NaCl, 50 Mm Tris-HCL \[pH 7.4\], 1 mM PMSF, 1 mM DTT, 1% NP-40 and protease inhibitor cocktail (PIC) tablet (Roche, Mannheim, Germany) in PBS. The primary antibodies were applied according to the provided recommendations: p-STAT3 (Tyr705), p-STAT3 (Ser727), pERK1/2 (Thr202/Tyr204), pJNK, STAT3, JNK, and ERK1/2 antibodies (Cell Signaling Technology Inc., Danvers, MA, USA). Blots were developed by the chemiluminescent substrate using X-ray film. Intensity of bands on the Western blots was quantified by Carestream MI software and the quantitative analyses of each gray numerical value of target protein *vs* that of individual β-actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA) or tubulin (Santa Cruz Biotechnology, Santa Cruz, CA, USA) were performed. The relative phosphorylation of target proteins was calculated by the ratios of phosphorylated proteins to β-actin and target proteins to β-actin.

2.8. Immunoprecipitation {#s0065}
------------------------

JEG3 and THP1 cells were lysed and immunoprecipitated with either an anti-ITI-H4 or an anti-KLKB1 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and immunoblotted with respective antibodies for detecting endogenous interaction between ITI-H4 and KLKB1. To identify the interaction between ITI-H4 and KLKB1, JEG3 cells were transfected with expression vectors encoding pCS4-3Flag-long ITI-H4, aa 1--902; pCS4-3Flag-ITI-H4 (∆N^688^), aa 689--902; and pCS4-3Flag-ITI-H4 (∆BKD), ∆aa 661--688. The cells were cultured for 48 h. The harvested cells were lysed with a lysis buffer (50 mM Tris, pH 7.6, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100) supplemented with protease inhibitor cocktail (Roche Diagnostics, Mannheim, Germany). Cell lysates were incubated with the corresponding antibody (2 μg) at 4 °C overnight then incubated with 30 μL of protein A/G PLUS Agarose (Santa Cruz Biotechnology, Santa Cruz, CA, USA) at 4 °C for 1 h. The samples were washed with a lysis buffer and resuspended in SDS samples buffer, and co-immunoprecipitated proteins were detected using Western blot analysis. The antibodies used for immunoblotting are anti-ITI-H4, anti-KLKB1, anti-Flag (Sigma, St, Louis, MO, USA), and anti-Myc antibodies (9E10, Santa Cruz Biotechnology, Santa Cruz, CA, USA).

2.9. Immunofluorescence microscopy {#s0070}
----------------------------------

JEG3 cells were seeded at 5 × 10^3^ per well into a 12-well culture dish (SPL Lifesciences, Gyeonggi-do, Korea), and cells were treated with or without IL-6 (10 ng/mL or 100 ng/mL). Cell staining procedure was followed as described previously \[[@bb0090]\]. Cell images were captured by using Nikon Eclipse 50i microscopy (Nikon, Melville, NY, USA).

2.10. RT-PCR and quantitative real-time PCR (qRT-PCR) {#s0075}
-----------------------------------------------------

RNAs from cells were extracted using the TRIzol™ (Invitrogen, Carlsbad, CA, USA). 2 μg total RNA for each sample was reverse--transcribed using the Oligo dT primer by Superscript™ II (Invitrogen, Carlsbad, CA, USA). RT-PCR was performed using the AccuPower™ PCR PreMix (Bioneer, Daejeon, Korea). The PCR conditions were as follows: initial melting (94 °C, 2 min), 35--40 cycles of amplification (94 °C, 20 s/45--65 °C, 30 s/72 °C, 30 s), and final extension (72 °C, 3 min). Concentration of each cDNA was normalized using the RT-PCR bands of *Gapdh*. qRT-PCR was performed using the SYBR® Green PCR Master Mix (Applied Biosystems, CA, USA), according to the manufacturer\'s instructions, in the ABI 7500 Real-time PCR System. All qRT-PCR results were normalized to *Gapdh* and *β-actin* levels. The primer sequences of the genes tested are shown in Supplemental Table 2.

2.11. Site-direct mutagenesis {#s0080}
-----------------------------

A catalytic mutant of KLKB1 (S578A) was generated by site-direct mutagenesis. Overlap extension PCR was performed for generation of pCS4-3Flag-ITI-H4 (∆BKD). The following primer sequences were used for generating mutants: KLKB1 (S578A); forward, 5′-TGT AAG GGA GAT GCA GGT GGT C-3′, reverse, 5'-ACT AAG GGA CCA CCT GCA TCT C-3′, BKD; forward, 5′-TGG CTC CCG GAT GAA TTT CAG ACG TCT GGC CAT CTT GCC TGC TT, reverse, 5′-AAG CAG GCA AGA TGG CCA GAC GTC TGA AAT TCA TCC GGG AGC CA-3′. After PCR reaction and gel purification, *Dpn* I enzyme (Enzynomics, Daejeon, Korea) was added and incubated for 1 h. Then, PCR products were transformed into DH5α competent cells, and DNA was extracted.

2.12. RNAi interference {#s0085}
-----------------------

siRNAs for ITI-H4 were generated with following sequences: \#1; 5'-CGA ACC ACC CAU UUG AGA U-3′, \#2; AUC UCA AAU GGG UGG UUC G, and KLKB1 siRNA; \#1; 5'-GUG CUU GCC AUC GAG ACA U-3′, \#2; AUG UCU CGA UGG CAA GCA C-3′ (Bioneer, Daejeon, Korea). 50 nM of ITI-H4 siRNA and KLKB1 siRNA were introduced into the cells by transfection using Opti-MEM and RNAimax (Invitrogen, Paisley, UK) according to the manufacturer\'s instructions. The same concentration of non-targeting siRNA (Santa Cruz Biotechnology, sc-37,007) was used as a control.

2.13. Cell counting kit-8 assay {#s0090}
-------------------------------

100 μL of transfected THP1 cell suspension having 50,000--100,000 cells/mL was added to 96-well plate. The protocol was followed according to the instructions provided by the company (Dojindo Molecular Technologies, Rockville, MD, USA). O.D. was measured at 450 nm to determine the cell viability in each well.

2.14. Transwell invasion and migration assay *in vitro* {#s0095}
-------------------------------------------------------

Invasion assays were performed in triplicate using transwell invasion chambers coated with Matrigel (50 μL per filter) (BD Biosciences, Franklin Lakes, NJ, USA) as described in the manufacturer\'s protocol. Migration assays were performed using a 12-well Transwell chamber system (Costar 3422, Corning Inc., Oneonta, NY, USA). Cells were seeded in the upper chamber at 1.5 x 10^5^cells/mL in 0.1 mL serum-free RPMI-1640 or DMEM media. After incubation for 24 h at 37 °C in an atmosphere containing 5% CO~2~, migrated or invasive cells on the lower surface were stained with crystal violet stain and counted under a light microscope. All experiments were repeated six times over several days.

2.15. Glutathione S-transferase (GST) pull-down assay {#s0100}
-----------------------------------------------------

ITI-H4 subcloned into glutathione S-transferase (GST)-tagged vector was transformed and expressed in BL21 *E. coli* strain. Bacterial lysate expressing GST-ITI-H4 was used to purify proteins using Glutathione-Sepharose Beads (GE Healthcare, Buckinghamshire, England), according to the manufacturer\'s instructions. JEG-3 cells were transfected with Myc-KLKB1. After 24 h of incubation, the cells were harvested and suspended in Buffer A (20 mM Tris-HCl at pH 8.0, 1 mM EDTA, 1 mM dithiothreitol, 150 mM NaCl, 1% Triton X-100) containing 1× protease inhibitor mixture (Complete™ Roche Applied Science, Mannheim, Germany). Purified GST-ITI-H4 proteins were confirmed by Coomassie Brilliant Blue staining. To check the interaction between these proteins, GST or GST-ITI-H4 combined beads were incubated with JEG-3 cell lysates overexpressing Myc-KLKB1 and were tested by immunoblotting using anti-GST and anti-Myc antibodies.

2.16. Data processing and statistical analysis {#s0105}
----------------------------------------------

Statistical comparison between patients with RPL and the controls was made using Student\'s *t-*test and Wilcoxon\'s test (SPSS 19.0). Pearson\'s or Spearman\'s correlation coefficient was calculated to estimate the interrelationships between gene expression levels and the distributions of relevant variables. *P-*values \<.005 or \< .05 were considered statistically significant. Comparisons between two groups of cells were made with a *t-*test (GraphPad Prism 4.0, GraphPad Software, Inc., San Diego, CA, USA). All experiments were repeated at least three times, and differences with *P-*values of \<.05 were considered statistically significant.

3. Results {#s0110}
==========

3.1. ITI-H4 (∆N^688^) expression is elevated in sera of RPL patients {#s0115}
--------------------------------------------------------------------

To determine the change in ITI-H4 expression in the sera of RPL patients, we extended the number of samples with an additional set of 60 RPL patients and 30 controls. Interestingly, the long isoform of ITI-H4 expression was only found in normal control women. In contrast, the ITI-H4 (∆N^688^) was present in approximately 50% of RPL patients (Supplementary Fig. S1a). We further measured serum levels of inflammatory markers (TNF-α, IL-6, IL-4, IL-10, IL-13, IL-1β, IFN-γ and IL-2) with freshly collected blood samples of control subjects (n = 30) and patients with RPL (n = 60). Interestingly, the expression of pro-inflammatory cytokines/chemokines was significantly increased and the anti-inflammatory cytokine/chemokine was decreased in freshly collected blood samples of RPL patients compared to those of normal subjects (Supplementary Fig. S1b).

3.2. The differential expression of ITI-H4 and KLKB1 in PBMCs of controls and RPL patients {#s0120}
------------------------------------------------------------------------------------------

To verify the change in the level of ITI-H4 and KLKB1 in the PBMCs of RPL patients, we isolated PBMCs from 10 RPL patients and 10 controls. *ITI-H4* mRNA levels were decreased in the PBMCs of RPL compared with those to the control group, while the mRNA levels of *KLKB1* were significantly increased (approximately two-fold) in the PBMCs from RPL ([Fig. 1](#f0005){ref-type="fig"}A and Supplementary Fig. S2). In addition, the protein level of long isoform of ITI-H4 was reduced in RPL PBMC samples compared with control samples, whereas the protein level of ITI-H4 (∆N^688^) in RPL PBMC samples was higher than in control samples (Supplementary Fig. S3a-d). Moreover, on the protein level, the expression of KLKB1 was significantly higher in RPL PBMC samples compared with control samples (Supplementary Fig. S4a-b). The imbalance of pro- and anti-inflammatory cytokine expression might lead to recurrent miscarriage during pregnancy period, and previous reports have shown elevated concentrations of specific circulating pro-inflammatory markers in RPL patients \[[@bb0050]\]. We evaluated the status of inflammation in the PBMCs in the subjects by analyzing the mRNA levels of *TNF-α, IL-6, IL-4, IL-10, IL-13, IL-1β, IFN-γ* and *IL-2* in their PBMCs. As expected, the expression of pro-inflammatory genes at the mRNA level was clearly elevated in the PBMCs in the RPL group compared with that in the control group ([Fig. 1](#f0005){ref-type="fig"}B and Supplementary Fig. S5). Through a validated activity assay, we were able to confirm significantly increased level of KLKB1 in RPL patients ([Fig. 1](#f0005){ref-type="fig"}C). In addition, we also checked the correlation between ITI-H4 levels and inflammation status, and found that the *ITI-H4* mRNA levels in PBMCs positively correlated with the expression of inflammatory factors (Supplementary Fig. S6).Fig. 1Elevated expression of ITI-H4 and KLKB1 in PBMCs of RPL patients. (A) Relative mRNA expression of *ITI-H4* and *KLKB1* in PBMCs of 10 RPL patients and 10 controls. (B) Relative mRNA expression of inflammatory factors (*TNF-α, IL-6, IL-4, IL-10, IL-13, IL-1β, IFN-γ,* and *IL-2*) in PBMCs of RPL patients and controls. Data are presented as a means ± SD. \*, *P* \< .05; \*\*, *P* \< .01. (C) KLKB1 activity assay identified an elevation of KLKB1 activity with the cleaved KLKB1 activity was also found to be reduced in patients with RPL when compared to controls. Data are presented as a means± SD. \*, *P* \< .05; \*\*, *P* \< .01.Fig. 1

3.3. The enhanced expression of ITI-H4 (∆N^688^) and activation of IL-6 cascade modulators in human monocytes {#s0125}
-------------------------------------------------------------------------------------------------------------

In the current study, we showed that IL-6 as an inflammatory mediated factor might lead to increased levels of ITI-H4 (∆N^688^) and KLKB1 in human monocytic THP1 cells ([Fig. 2](#f0010){ref-type="fig"}A-[2](#f0010){ref-type="fig"}D). In addition, stimulation with IL-6 activates STAT3, ERK, and JNK within 30--60 min ([Fig. 3](#f0015){ref-type="fig"}A-[3](#f0015){ref-type="fig"}D). The IL-6-mediated induction of ITI-H4 expression could be significantly decreased by treatment with an ERK inhibitor (PD98059) or a specific JNK inhibitor (SP600125), and a STAT3 inhibitor (LLL12) ([Fig. 3](#f0015){ref-type="fig"}E and F). Thus, these findings suggest that expression of ITI-H4 (∆N^688^) is induced in human monocytic THP1 cells upon IL-6 stimulation in a STAT/MAPK-dependent manner.Fig. 2IL-6 regulates the expression of ITI-H4 and KLKB1 in human monocytes. (A) THP1 cells time-dependently treated with 20 ng/mL of IL-6 were lysed and the long isoform of ITI-H4 and the ITI-H4 (∆N^688^), and KLKB1 protein levels were detected by Western blotting. (B)- (D) Quantitative density of gel bands for ITI-H4 and KLKB1. Each experiment was repeated three times.Fig. 2Fig. 3ITI-H4 expression is induced by IL-6 in a STAT- and MAPK dependent manner. (A) THP1 cells were incubated for the indicated time points with IL-6. Then, ERK, STAT3, and JNK activation were assessed for total and phosphorylated signaling proteins by Western blot analysis. β-actin was used as a control. pERK, phospho-ERK; pSTAT3, phospho-STAT3; and pJNK, phospho-JNK. (B)-(D) the curves represent a means± SD of density of gel bands determined by Western blotting. (E) Cells were preincubated with SP600125 (a JNK inhibitor), PD98059 (an ERK inhibitor), or LLL12 (a STAT3 inhibitor) before treatment with IL-6. ITI-H4 expression is also shown. (F) ITI-H4 expression level was normalized to the one of β-actin. All statistical data are presented as a means (*n* = 3~,~ \*, *P* \< .05).Fig. 3

Then, we determined whether inflammatory stimuli enhance the expression of ITI-H4 in human CD14+ monocyte cells, human CD14+ monocytes were treated with 20 ng/mL of IL-6 for 12 h. Interestingly, IL-6 induces the activation of STAT3, ERK, and JNK pathway within 20--30 min (Supplementary Fig. S7a). Because ITI-H4 expression is induced by inflammation, we investigated the role of ITI-H4 in the inflammatory response. We examined the effect of ITI-H4 knockdown on the expression of inflammatory factors in human monocytes (Supplementary Fig. S7b and S8). The expression of these pro-inflammatory genes (*TNF-α, IL-6, IL-1β,* and *IFN-γ*) were all markedly induced and the anti-inflammatory genes (*IL-4, IL-10, IL-13,* and *IL-2*) were downregulated after knockdown of ITI-H4. These results suggest that ITI-H4 expression is enhanced in human CD14+ monocytes by treatment of inflammatory stimuli in an IL-6-dependent manner. Furthermore, ITI-H4 could positively or negatively regulate the Th1 and Th2 cytokines with potential pro- and anti-inflammatory activities. A previous report suggests that pig MAP is an IL-6-dependent acute-phase protein in porcine primary cultured hepatocytes \[[@bb0085]\]. Thus, we hypothesized that the human ITI-H4 is also regulated by IL-6 in human hepatocellular cells. To confirm this effect in a quantitative manner, we treated hIL-6 at doses of 100 and 1000 U/mL for various time intervals (0, 2, 6, 24, and 48 h) in human hepatocellular cells. Interestingly, we found that IL-6 induced an increase of human ITI-H4 both at the mRNA and protein levels. However, we could not detect the ITI-H4 (∆N^688^) in human hepatocellular cells (Supplementary Fig. S9a-d).

To investigate cellular localization of ITI-H4, we performed immunofluorescent staining of endogenous ITI-H4. Our result revealed that IL-6 altered ITI-H4 expression and translocation. Thus, we further checked ITI-H4 localization in the presence of IL-6. Without IL-6 treatment, ITI-H4 is mainly localized in the nucleus (Supplementary Fig. S10a, middle panel). However, it is of interest that the nuclear localization of ITI-H4 is abrogated in IL-6-induced condition (Supplementary Fig. S10b, middle panel, 10 ng/mL; Supplementary Fig. S10c, middle panel, 100 ng/mL.

3.4. ITI-H4 interacts with KLKB1, and KLKB1 stabilizes ITI-H4 protein in a dose dependent manner {#s0130}
------------------------------------------------------------------------------------------------

The C-terminus of human ITI-H4 contains a proline-rich region (PRR; Gly^611^-Gln^730^), which extends 120 residues in length and harbors species- and tissue-specific domains \[[@bb0095],[@bb0100]\]. In addition, protein von Willebrand factor type A (Vwf) domains are typically involved in protein-protein interactions and glycosylation at this site might potentially affect ITI-H4 interactions with other proteins \[[@bb0105]\]. Moreover, the bradykinin-like fragment (Pro^622^-Arg^688^) within the PRR may play an important role in inflammatory response during acute inflammation \[[@bb0110]\]. The detailed domain information of ITI-H4 is illustrated (Supplementary Fig. S11a). Bradykinin domain (BKD) is the only domain located towards the C-terminal region of ITI-H4. Interestingly, the BKD domain-deleted ITI-H4 showed relatively less interaction with KLKB1 compared to the long isoform of ITI-H4 (Supplementary Fig. S11b). In addition, we found that an anti-ITI-H4 antibody could co-precipitate endogenous KLKB1, and the level of ITI-H4 protein dramatically decreased in the presence of KLKB1 in a dose dependent manner (Supplementary Fig. S11c-11d). However, a catalytic mutant KLKB1 (S578A) failed to reduce the level of ITI-H4 (Supplementary Fig. S11e). In a GST pull-down assay, KLKB1 from cell lysates was pulled down by GST-ITI-H4 bound beads, suggesting that ITI-H4 directly binds to KLKB1 (Supplementary Fig. S11f). Our result suggests that the KLKB1 acts as a specific protease for ITI-H4 regulating its protein stability.

3.5. ITI-H4 regulates pro- and anti-inflammatory cytokines/chemokines in human placental choriocarcinoma cells {#s0135}
--------------------------------------------------------------------------------------------------------------

To investigate the role of ITI-H4 in the inflammatory response in human choriocarcinoma cells, we examined the effect of ITI-H4 knockdown on the expression of inflammatory factors in JEG-3 cells ([Fig. 4](#f0020){ref-type="fig"}A, B and Supplementary Fig. S12). The expression of these pro-inflammation-related genes (*TNF-α, IL-2, IL-1β,* and *IL-6*) were markedly induced, while anti-inflammation-related genes (*IL-4, IL-10*, and *IL-13*) were clearly inhibited after down-regulation of ITI-H4, indicating that ITI-H4 is involved in modulating inflammation in human placental choriocarcinoma cells. These results show that ITI-H4 regulates the pro- and anti-inflammatory genes in human choriocarcinoma cells.Fig. 4Knockdown of ITI-H4 regulates the expressions of inflammatory factors in human placental choriocarcinoma cells. (A) Relative mRNA expression of *ITI-H4*. (B) Relative mRNA expression of inflammatory factors after *ITI-H4* siRNA treatment in human placental choriocarcinoma cells. Data are presented as a means± SD (n = 3). \*, *P* \< .05.Fig. 4

3.6. The opposing inflammatory functions of two different isoforms of ITI-H4 {#s0140}
----------------------------------------------------------------------------

To further investigate the molecular inflammatory roles of the long isoform of ITI-H4 and ITI-H4 (ΔN^688^), we examined the effect of overexpression of two different forms in human placental choriocarcinoma cells. The expression of these pro-inflammatory-related cytokines (TNF-α, IFN-γ, IL-1β, IL-2, and IL-6) was significantly increased after the cells were transfected with the ITI-H4 (∆N^688^). Nevertheless, anti-inflammatory cytokines (IL-4, IL-10, and IL-13) were upregulated after the cells were transfected with the long isoform of ITI-H4 ([Fig. 5](#f0025){ref-type="fig"}A-[5](#f0025){ref-type="fig"}C). Additionally, our data suggest that ITI-H4 might be regulated by KLKB1 *in vitro* and *in vivo*. We also checked the inflammatory roles of KLKB1 and its catalytic mutant KLKB1 (S578A) ([Fig. 5](#f0025){ref-type="fig"}D). Interestingly, KLKB1 overexpression enhanced the production of pro-inflammatory cytokines/chemokines which might be involved in inflammatory response. Furthermore, overexpression of the long isoform of ITI-H4 and KLKB1 resulted in significant increase of pro-inflammatory cytokines expression, while transfection of the long isoform of ITI-H4 along with KLKB1 (S578A) caused upregulation of anti-inflammatory cytokines compared with the co-transfection of the long isoform of ITI-H4 and KLKB1 ([Fig. 5](#f0025){ref-type="fig"}E), indicating specific protease activity of KLKB1 on ITI-H4. Consequently, our results are suggestive of KLKB1\'s ability to interact and stabilize ITI-H4 expression to affect immune response and production of cytokines/chemokines. The expression level of individual constructs was checked by Western blot analysis (Supplementary Fig. S13a-13c).Fig. 5The related signaling pathway by which ITI-H4 and KLKB1 overexpression regulates the inflammatory factors in human placental choriocarcinoma cells. (A) Relative mRNA expression of inflammatory factors after transfection with the ITI-H4 (∆N^688^), the long isoform of ITI-H4, and ITI-H4 (∆BKD). (B) The ratios of Th1/Th2 cytokines are indexed by TNF-α/IL-10 and IFN-γ/IL-10, and data were presented as a means with SD. (C) Flow cytometric assay of cytokines expressions (IFN-γ, TNF-α, and IL-4) in the supernatants of transfected cell cultures. (D) Relative mRNA expression of inflammatory factors after KLKB1 and KLKB1 (S578A) transfection. (E) Relative mRNA expression of inflammatory factors after the long isoform of ITI-H4 and KLKB1 expression vector co-transfection, or the long isoform of ITI-H4 and KLKB1 (S578A) co-transfection. (F) Phosphorylation of STAT3, ERK, and JNK after the ITI-H4 (∆N^688^) overexpression by Western blotting. (G) Relative mRNA expression of inflammatory factors (*TNF-α, IL-6, IL-1β, IFN-γ, and IL-2*) after the ITI-H4 (∆N^688^) expression vector transfection and inhibitor treatments of specific pathways (SP600125, JNK phosphorylation inhibitor; PD98059, ERK phosphorylation inhibitor; and LLL12, STAT3 phosphorylation inhibitor) (n = 4).(H) Western blotting analysis of ERK, phosphorylated ERK, STAT3, and phosphorylated STAT3 expression in treated JEG-3 cells (n = 3). Data are presented as a means± SD. \*, *P* \< .05 *versus* the ITI-H4 (∆N^688^) expression vector transfection (Flag-ITI-H4 (∆N^688^). Data are presented as a means± SD. \*, *P* \< .05; \*\*, *P* \< .01; \*\*\*, *P* \< .001.Fig. 5

3.7. ITI-H4 (∆N^688^)-induced cytokine and chemokine expression is dependent on STAT and MAPK pathways {#s0145}
------------------------------------------------------------------------------------------------------

Further to determine the signaling cascade, we examined the activation of STAT, ERK, and JNK molecules after overexpression of the ITI-H4 (∆N^688^) by Western blotting ([Fig. 5](#f0025){ref-type="fig"}F). Phosphorylation of STAT3 and ERK was enhanced after transfection with ITI-H4 expression vector, while a slight change of phosphorylation of JNK was detected after ITI-H4 (∆N^688^) overexpression ([Fig. 5](#f0025){ref-type="fig"}G and Supplementary Fig. S14). Remarkably, the ERK phosphorylation inhibitor PD98059, the JNK phosphorylation inhibitor SP600125, and STAT3 phosphorylation inhibitor LLL12 blocked the increase in the ITI-H4 (∆N^688^), which reduced the activation of STAT, ERK, and JNK, compared to their normal activation levels ([Fig. 5](#f0025){ref-type="fig"}H). Taken together, these results suggest that ITI-H4 (∆N^688^)-induced inflammation and immune response are dependent on the STAT, ERK, and JNK signaling pathways.

3.8. ITI-H4 and KLKB1 regulate cell invasion in human placental choriocarcinoma cells {#s0150}
-------------------------------------------------------------------------------------

Several lines of evidence have suggested that IL-6/STAT3 pathway affects cell invasion and migration \[[@bb0115], [@bb0120], [@bb0125]\]. Analysis of invasion behavior of the transfected JEG-3 cells indicates that the ITI-H4 (∆N^688^)- or KLKB1-transfected cells showed significant reduction in invasion when compared to that of the controls. The co-transfection of the long isoform of ITI-H4 and KLKB1 displayed significantly reduced invasion in comparison to that of cells transfected with the long isoform of ITI-H4 alone ([Fig. 6](#f0030){ref-type="fig"}A and B). Western blotting was performed to determine the exogenous level of the long isoform of ITI-H4, ITI-H4 (ΔN^688^), and KLKB1 (Supplementary Fig. S15a). In addition, knockdown of both ITI-H4 and KLKB1 expression resulted in an increase in the number of invasive cells compared with the ITI-H4 knockdown alone ([Fig. 6](#f0030){ref-type="fig"}C and D). The designed siRNAs for ITI-H4 and KLKB1 effectively depleted endogenous ITI-H4 and KLKB1 in JEG-3 cells (Supplementary Fig. S15b). Taken together, it is suggested that the ITI-H4 (∆N^688^) could inhibit cell invasion, and the functional interaction between ITI-H4 and KLKB1 is essential for the regulation of cell invasion.Fig. 6The ITI-H4 (∆N^688^) affects invasion of the human choriocarcinoma cells and human macrophage migration. (A) Invasion assay. JEG-3 cells transfected with respective constructs and kept in the medium containing G418 (400 μg/mL), seeded in Matrigel-coated invasion plates and incubated for 48 h. (B), (D) The invading cells on the underside of the membrane were enumerated by using an inverted microscope in 10 random fields (10 × 10). Experiments were performed in triplicate and the results are represented as a means of invasion cell numbers. n = 3, \*, *P* \< .05; \*\*, *P* \< .01; ns, not significant. (C) JEG-3 cells 48 h after transfection with siControl, siITI-H4, siKLKB1 or siITI-H4/siKLKB1, were analyzed using a Matrigel-coated Transwell. Cells successfully invaded into the Matrigel were quantified 48 h after plating. (E) The transwell assay showed that ITI-H4 overexpression at 36 h promoted human macrophage migration. (F) Data are presented as a means ± SD (N = 3). \*, *P* \< .05, \*\*, *P* \< .01, *versus* control vector transfection (Flag group).Fig. 6

3.9. The ITI-H4 (ΔN^688^)-overexpressed JEG-3 cells could enhance macrophage migration {#s0155}
--------------------------------------------------------------------------------------

After confirming the induction of ITI-H4 expression by inflammatory response, we next questioned the role of the long isoform of ITI-H4 and the ITI-H4 (∆N^688^) in the inflammatory response. We investigated the effect of ITI-H4 on macrophage migration, which is a hallmark of the immune response for disposal invasions. As mentioned in Materials and Methods, JEG-3 cells were transfected with Flag-tagged long ITI-H4 and ITI-H4 (∆N^688^) along with the empty Flag vector, and were placed in the bottom wells for 36 h. Macrophages were resuspended after overnight culture in serum-free RPMI-1640, and then added to the upper chamber in serum-free RPMI-1640. After 4 h of incubation, the number of migrating cells was determined. Interestingly, the long isoform of ITI-H4-overexpressed JEG-3 cells could successfully inhibit chemotactic migration of human macrophage, while the ITI-H4 (∆N^688^)-overexpressed JEG-3 cells could enhance human macrophage migration ([Fig. 6](#f0030){ref-type="fig"}E and F), indicating that the ITI-H4 (∆N^688^) acts as a chemoattractant to drive integration of cytokines and chemokines in human JEG-3 cells. Western blotting was performed to determine the exogenous level of the long isoform ITI-H4 and ITI-H4 (ΔN^688^) (Supplementary Fig. S15c).

3.10. Cell proliferation assay {#s0160}
------------------------------

Our data suggest that the ITI-H4 (∆N^688^) could promote macrophage migration, which might modulate immune response. To further investigate the effect of the long isoform of ITI-H4 and ITI-H4 (∆N^688^) on monocyte proliferation, we next conducted cell proliferation assay using cell counting kit-8 over 72 h in three separate experiments. Interestingly, the long isoform of ITI-H4 showed significant inhibition on human monocyte (THP1) cell proliferation, and the KLKB1 regulation of the long isoform of ITI-H4-mediated THP1 cell proliferation was identified ([Fig. 7](#f0035){ref-type="fig"}A). The ITI-H4 (∆N^688^) could promote THP1 cell proliferation in contrary to the long isoform of ITI-H4 ([Fig. 7](#f0035){ref-type="fig"}B). The expression level of individual constructs was checked by Western blot analysis (Supplementary Fig. S16a and 16b). Under the condition of ITI-H4 or KLKB1 gene silencing by siRNA, the block in cell proliferation caused by the long isoform of ITI-H4 greatly reduced ([Fig. 7](#f0035){ref-type="fig"}C). In addition, we observed possibility of KLKB1 regulation of THP1 cell proliferation ([Fig. 7](#f0035){ref-type="fig"}C). The knockdown efficiency of siITI-H4 and siKLKB1 was checked by Western blot analysis in THP1 cells (Supplementary Fig. S16c). Collectively, our data showed that the long isoform of ITI-H4 and ITI-H4 (∆N^688^) might have the opposing effects on human monocytic cell proliferation. Intriguingly, KLKB1 and ITI-H4 mutually interact with each other to regulate cell proliferation.Fig. 7Cell proliferation assay and Co-culture with human choriocarcinoma cells and serum derived from RPL patients or normal groups. (A), (B) Human monocytic cells were transfected with respective constructs and cell proliferation was assessed by cell counting kit-8 assay over 72 h. A means ± SD of a triplicate experiment is shown. (C) Human monocytic cells were transfected with *ITI-H4* or *KLKB1* siRNA. At three different time points after transfection cell proliferation ratio was analyzed using live cell staining buffer (CCK-8, cell counting kit-8), then read using 450 nm filter. \*, *P* \< .05, \*\*, *P* \< .01, \*\*\*, *P* \< .001. ns, not significant. Data were analyzed by a two-way analysis of variance, and significant differences were determined by Tukey-Kramer test (n = 3). (D) JEG-3 cells were cultured in DMEM supplemented with 5% FBS, 5% serum derived from RPL patients or normal groups, respectively. After incubation in 37 °C for 24 h, cell images were captured using electron microscopy, and, (E) the relative expressions of inflammatory cytokines (*TNF-α, IL-4, IL-10, IL-2, IFN-γ,* and *IL-6*) were measured. Data are presented as a means± SD (n = 3). (F) Schematic presentation of molecular mechanism for induced inflammation mediated by the increased expression of ITI-H4 (∆N^688^) in RPL. The long isoform of ITI-H4 is expected to be cleaved by KLKB1, and KLKB1 regulates ITI-H4, altering immune signaling factors, proliferation rates, invasion or macrophage migration. In RPL, ITI-H4 could elevate the expression of anti-inflammatory factors, while the ITI-H4 (∆N^688^) induced pro-inflammatory factors. Similarly, the long isoform of ITI-H4 and ITI-H4 (∆N^688^) possess opposing functions on immune tolerance, trophoblast invasion, and monocytes migration or proliferation.Fig. 7

3.11. Co-culture with human choriocarcinoma cells and serum derived from RPL patients or normal groups {#s0165}
------------------------------------------------------------------------------------------------------

We hypothesized that the ITI-H4 (ΔN^688^) might be closely interconnected or involved in the pathogenesis of RPL, since the ITI-H4 (ΔN^688^) was highly expressed in the serum derived from RPL patients. For this purpose, we investigated the functional role of ITI-H4 using the co-culturing system. JEG-3 cells were separately cultured in DMEM medium supplemented with 5% FBS, and serum (5%) pooled from RPL patients or normal women groups for 24 h. Each group contains 6--7 women. The long isoform of ITI-H4 was highly expressed in both normal group 1 and 2, and the ITI-H4 (ΔN^688^) was highly expressed in all of patients belonging to the RPL group 1 and 2. Based on our previous study, we chose group 3 serum samples which showed both forms of ITI-H4. In addition, the captured microscopy images were shown in [Fig. 7](#f0035){ref-type="fig"}D. Strikingly, we observed 'jelly coat' type in normal women group 1 and 2 (Supplementary Fig. S17a and [Video 1](#ec0005){ref-type="supplementary-material"}, [Video 2](#ec0010){ref-type="supplementary-material"}, [Video 3](#ec0015){ref-type="supplementary-material"}, [Video 4](#ec0020){ref-type="supplementary-material"}. Mp4), and approximately 70--80% of cell death was quantified by trypan blue staining in RPL group 1 and 2. Then, we measured relative cytokine expressions in those samples. As expected, the pro-inflammatory cytokines (*TNF-α, IL-2,* and *IFN-γ*) are increased in RPL group samples, while the anti-inflammatory cytokines (*IL-4* and *IL-10*) were upregulated in normal group samples ([Fig. 7](#f0035){ref-type="fig"}E). Altogether, to some extent, our findings demonstrate that ITI-H4, particularly the ITI-H4 (∆N^688^) that was present in the RPL serum, could upregulate pro-inflammatory cytokines. Additionally, invasion analysis indicates that the RPL group 1 and 2-cocultured cells showed significant reduction in invasion when compared to that of the normal groups 1 and 2 (Supplementary Fig. S17b and S17c). Similarly, high expression of *matrix metalloproteinase-9 (MMP-9)*, but not *MMP-2*, *mucin 1 (MUC1)* or *human placental protein (PP14)*, was observed in RPL groups 1 and 2 (Supplementary Fig. S17d and S18).

4. Discussion {#s0170}
=============

There are increasing lines of evidence suggesting a role of chronic or acute inflammation in the pathogenesis of RPL, which is demonstrated by persistent, moderately elevated concentrations of cytokines, chemokines and circulating C-reactive protein. The paradoxical success of the "fetal allograft" in the face of a potentially hostile maternal immune system has been suggested to be due to immunomodulation at the maternal-fetal interface and a consequent lack of strong maternal cell-mediated anti-fetal reactivity of the T helper 1 (Th1) type \[[@bb0130],[@bb0135]\]. Several studies on animal models of pregnancy and a few on human pregnancies have led to the proposition that successful pregnancy is a T helper 2 (Th2) phenomenon, while vigorous Th1-type immunity, mediated by Th1-type cytokines, is deleterious to pregnancy \[[@bb0140],[@bb0145]\]. Therefore, the balance of Th1/Th2 cytokines is essential to maintain pregnancy. Here, we observed the high expression of TNF-α, IL-2, IL-1β, and IFN-γ which belong to Th1 cytokines in RPL patients, while Th2 cytokines, particularly like IL-4 and IL-10, are upregulated in control group. In addition, we observed the long isoform of ITI-H4 in normal women; however, approximately 76.9% of ITI-H4 (∆N^688^) was detected in RPL women \[[@bb0060]\]. Compared to our previous study \[[@bb0060]\], the current study enlarges the sample size to 30 controls and 60 RPL patients; nevertheless, the ITI-H4 (∆N^688^) still occupies a large proportion in RPL patients. Moreover, increased the expression of KLKB1 and decreased mRNA expression of *ITI-H4* in PBMCs of RPL patients compared with those in the controls, and the ITI-H4 expression patterns were correlated with the expression of inflammatory markers. It is reasonable to surmise that an imbalance between ITI-H4 and KLKB1 levels is associated with inflammation in RPL patients. The role of ITI-H4 in RPL remains undetermined and no functional mechanism study has yet been performed that concerns RPL. The structure of the proteins of ITI family has been widely studied \[[@bb0150],[@bb0155]\]. Because of its sensitivity to kallikrein degradation, it was later considered as a kallikrein substrate, and known as PK-120 \[[@bb0160]\]. ITI-H4 has several putative domains, and previous studies have demonstrated that some of these domains were also found to be associated with different diseases \[[@bb0165]\]. In addition, the bradykinin-like fragment (Pro^662^-Arg^688^) within the PRR is assumed to take part in inflammatory response during acute inflammation \[[@bb0115]\]. The BKD contains the KLKB1 cleavage site (R688). In our previous LC-MS/MS analysis and the current study have identified the cleavage site of ITI-H4 fragmentation \[[@bb0060]\]. Further domain functional studies also suggested that the BKD domain might play important roles in immune response which might be involved in the pathogenesis of RPL.

Furthermore, it is worth noting that elevated IL-6 is frequently evident in the altered cytokine profiles characteristic of unexplained infertility, recurrent miscarriage, and preterm delivery \[[@bb0140]\]. In addition, RPL is accompanied by increased IL-6 trans-signaling systemically, yet it is still controversial \[[@bb0170]\]. IL-6 is a multifunctional cytokine with pivotal roles in the inflammatory response and there is significant relationship between IL-6 signaling components and T cell responses in pregnant women \[[@bb0170]\]. And excessive IL-6 bioavailability potentially inhibiting generation of CD4+ T regulatory cells is required for pregnancy tolerance \[[@bb0140]\]. Interestingly, IL-6 as an inflammatory mediated cytokine could increase the KLKB1 level and stimulate the production of ITI-H4 (∆N^688^), while the long isoform of ITI-H4 was decreased in monocytes. We also observed IL-6 activates the downstream signaling factors of STAT and MAPK pathways in human CD14+ monocytes. In addition, knockdown of ITI-H4 in human CD14+ monocytes could upregulate pro-inflammatory cytokines expression. Additionally, challenge with the inflammatory cytokine IL-6 could upregulate the expression of ITI-H4 (∆N^688^), and SP600125, PD98059, or LLL12 inhibitors blocked this response.

Our further functional studies have also demonstrated that expression of Th1 cytokines was increased after overexpression of the ITI-H4 (∆N^688^), while Th2 cytokines were upregulated after the cells were transfected with the long isoform of ITI-H4. Our data suggest that the long isoform of ITI-H4 might play positive roles in the maintenance of Th1/Th2 balance, while ITI-H4 (∆N^688^) does not ([Fig. 7](#f0035){ref-type="fig"}F).

In addition, IL-6 plays a regulatory role in trophoblast invasion, migration or proliferation \[[@bb0175]\]. It has been suggested that ITI-H4 may have a role in protecting the uterus from the inflammatory response induced by conceptus attachment to the uterine epithelium \[[@bb0175]\]. To gain a better insight into the mechanism underlying ITI-H4 involved in the pathogenesis of RPL, we hoped to identify the functional differences between the long isoform of ITI-H4 and ITI-H4 (∆N^688^) regarding immune modulation, trophoblast cell invasion, immune cell migration or proliferation.

Moreover, additional invasion analysis using above co-culturing system, the RPL groups-cocultured cells showed decreasing invasion when compared to that of the normal groups. And we also observed the expression of immunity-related genes was decreased in the RPL group-cocultured cells, such as *PP14* and *MUC1*. In our previous studies have also suggested that these factors were aberrantly expressed in chorionic villi from RPL patients \[[@bb0050]\]. Approximately 25% of RPL patients has shown the elevation of immune response to trophoblast and increased proliferation of inflammatory cells \[[@bb0180]\]. This leads to the possibility that aberrant regulation of immunosuppression-related gene products may cause RPL. PP14 has important roles as a possible immunosuppressive molecule capable of successful pregnancy and growth of the fetus \[[@bb0015]\]. In addition, adhesion molecules such as MUC1 play an important role in apposition and adhesion, followed by trophoblast invasion through the pinopode formation \[[@bb0185]\]. It has also been suggested that decreased expression of MUC1 might induce endometrial super-fertility and interrupt embryo selection, which allows defective blastocysts to implant but leads to increase miscarriage rate \[[@bb0190]\]. Moreover, MMP-2 and MMP-9 were found to be involved in successful cytotrophoblast invasion in early pregnancy \[[@bb0195]\] . We suggest that 'jelly-coat' phenotype formation in normal women groups might be closely related to the normal immune response or invasion, while the RPL group-cocultured might be involved in a strong inflammatory response in pregnant women, and consequently the pregnancy may fail.

Taken together, it is suggested that the long isoform of ITI-H4, ITI-H4 (∆N^688^), and KLKB1 play important roles in the maintenance of homeostasis in pregnancy, and deregulation of IL-6 pathway showed a vicious circle that might be involved in the pathogenesis of recurrent miscarriage. This is the first study on a novel cellular mechanism underlying RPL. Our present study pointed to the opposing roles of the long isoform of ITI-H4 and ITI-H4 (ΔN^688^) in modulating inflammatory response, cell invasion, migration or proliferation. And the ITI-H4 (∆N^688^) might be a crucial inflammatory factor which contributes to the pathogenesis of RPL.

The Supplementary Material for this article can be found online.
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[^1]: Numerical data were presented as a means ± standard deviation (SD) or n; NS not significant. Abbreviations: BMI, Body mass index

[^2]: *p* \< .05.
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